more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,060.86 USD

+5.29 (0.50%)

Updated Jul 24, 2024 04:00 PM ET

Pre-Market: $1,065.30 +4.44 (0.42%) 8:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod

by Arpita Dutt Published on June 29,2017

Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.

Neothetics' Fat Reduction Candidate Fails in Phase II Study

by Zacks Equity Research Published on June 28,2017

Neothetics, Inc. (NEOT) announced disappointing top line results from a phase II proof-of-concept study, LIPO-202-CL-31, evaluating its lead candidate, LIPO-202, for reduction of submental subcutaneous fat.

Esperion's Combo Cholesterol Candidate Enters Phase III

by Zacks Equity Research Published on June 28,2017

Esperion Therapeutics, Inc. (ESPR) received positive feedback from the FDA for initiation of a phase III bridging study, evaluating the combination of bempedoic acid (180 mg) and Zetia (10 mg) for an LDL-C lowering indication.

Teva/Xenon Nerve Pain Candidate Fails in Phase II Study

by Zacks Equity Research Published on June 28,2017

Teva Pharmaceutical Industries Ltd. (TEVA) announced that a mid-stage study evaluating their pipeline candidate, topical TV-45070 for post-herpetic neuralgia (PNH) did not meet the primary endpoint.

Strongbridge (SBBP) Shows Strength: Stock Moves Up 10.1%

by Zacks Equity Research Published on June 28,2017

Strongbridge Biopharma plc (SBBP) moved big last session, as the company saw its shares rise over 10% on the day.

5 Biomedical Stocks That Are Expected To Surge

by Jeffrey Hymen Published on June 27,2017

With the promise of regulatory reform on the horizon, investors have been excited about the biomedical space throughout the year. If you want to add some to your portfolio, check out these 5 biomedical stocks that are primed to skyrocket here.

Agios/Celgene's Leukemia Candidate Positive in Phase I/II

by Zacks Equity Research Published on June 27,2017

Agios Pharmaceuticals, Inc. (AGIO) has announced a positive efficacy and safety data from the ongoing phase I/II study on experimental candidate IDHIFA (enasidenib) at an oral session at the European Hematology Association (EHA).

Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU

by Zacks Equity Research Published on June 27,2017

Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.

Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion

by Zacks Equity Research Published on June 27,2017

Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion recommending marketing approval of a pediatric formulation of Mimpara for the treatment of secondary hyperparathyroidism

Conatus's PSC Candidate Gets Orphan Designation in the U.S.

by Zacks Equity Research Published on June 27,2017

Conatus Pharmaceuticals Inc. (CNAT) announced FDA's grant of Orphan Drug Designation (ODD) to its pipeline candidate IDN-7314 for treatment of primary sclerosing cholangitis.

Novartis Cardiovascular Drug Positive, NSCLC Drug Approved

by Zacks Equity Research Published on June 26,2017

Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.

Kamada Withdraws Inhaled AAT Marketing Application in EU

by Zacks Equity Research Published on June 23,2017

Kamada Ltd.'s (KMDA) decided to withdraw the marketing authorization application (MAA) for its inhaled formulation of Alpha-1 Antitrypsin (AAT) in the EU.

Here's Why Investors Are Glued to Vertex Pharma (VRTX) Stock

by Zacks Equity Research Published on June 23,2017

Vertex Pharmaceuticals, Inc. (VRTX), has been attracting investor attention.